Systemic Treatment of Severe Psoriasis
- 31 January 1991
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 324 (5) , 333-334
- https://doi.org/10.1056/nejm199101313240509
Abstract
The pathogenesis of psoriasis, which affects approximately 2 percent of the population of the United States and Northern Europe, remains obscure. It is recognized that the disease is genetically determined, but the precise mode of inheritance has not been defined.Psoriasis is most commonly of the plaque type, manifested by disfiguring erythematous scaling plaques that frequently localize on the extensor aspects of the body, especially the knees and elbows, and on the scalp. It can, however, become more extensive and occasionally affect entire areas of the body, and is then called erythrodermic or exfoliative psoriasis. Patients with extensive disease are . . .Keywords
This publication has 8 references indexed in Scilit:
- Cyclosporine for Plaque-Type PsoriasisNew England Journal of Medicine, 1991
- Etretin therapy for severe psoriasis. Evaluation of initial clinical responsesArchives of Dermatology, 1987
- Cyclosporine improves psoriasis in a double-blind studyJAMA, 1986
- Clearance of psoriasis with low dose cyclosporin.BMJ, 1986
- Etretinate therapy for psoriasis: Clinical responses, remission times, epidermal DNA and polyamine responsesJournal of the American Academy of Dermatology, 1983
- Risk of Cutaneous Carcinoma in Patients Treated with Oral Methoxsalen Photochemotherapy for PsoriasisNew England Journal of Medicine, 1979
- Evolution, maturation, and regression of lesions of psoriasisThe American Journal of Dermatopathology, 1979
- Abnormal Cell Proliferation in Psoriasis**From the Department of Dermatology, University of Miami School of Medicine, Miami, Florida.Journal of Investigative Dermatology, 1968